Publications

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

01-04-2014

Current opinion in oncology

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

01-03-2014

OncoTargets and therapy

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

19-12-2013

European journal of clinical pharmacology

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

01-12-2013

Nature medicine

High-throughput identification of antigen-specific TCRs by TCR gene capture.

01-11-2013

Acta oncologica (Stockholm, Sweden)

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

01-11-2013

Practical neurology

Neurological immune-related adverse events of ipilimumab.

01-08-2013

Cancer immunology, immunotherapy : CII

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

01-03-2013

The American journal of pathology

Targeting BRAFV600E in an inducible murine model of melanoma.

01-09-2012

Oncoimmunology

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

01-08-2012

Current oncology reports

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

01-06-2012

European journal of immunology

Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.

01-03-2012

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

10-01-2012

Melanoma research

Expression of the embryological morphogen Nodal in stage III/IV melanoma.

01-12-2011

Urology

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

01-10-2011

Journal of analytical toxicology

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

01-10-2011

Cancer immunology, immunotherapy : CII

Combination of targeted therapy and immunotherapy in melanoma.

01-10-2011

Current oncology reports

Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.

01-06-2011

Cancer

Overall survival and PD-L1 expression in metastasized malignant melanoma.

15-05-2011

Annals of oncology : official journal of the European Society for Medical Oncology

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.

01-05-2011

Cancer immunology, immunotherapy : CII

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.

01-08-2010

World journal of urology

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

01-08-2009

Nature methods

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

01-07-2009